

Quellen

1. Galle PR, Sangro B, Decaens T et al. Nivolumab plus ipilimumab vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: 4-year follow-up of CheckMate 9DW. ASCO Gastrointestinal Cancers Symposium 2026; Abstract #LBA479.